RBI-2000 / Replicate Biosci - LARVOL DELTA

A self-replicating RNA precision medicine approach to therapeutic protein delivery of narrow therapeutic index biomolecules (AACR 2023) - "RBI-2000 is a novel srRNA encapsulated in a lipid nanoparticle and encoding two distinct proteins on the same strand of RNA...Tumor re-challenge of the mice at a site distal to the original implantation showed 100% protection. Collectively, these data demonstrate the feasibility of novel srRNA vectors as a protein drug replacement approach including for the expression of complex, multimeric cocktails of proteins."

Oncology

Replicate Bioscience Presents Preclinical srRNA Data at the American Association for Cancer Research Annual Meeting 2023 (PRNewswire) - "Replicate Bioscience...shared new preclinical data underscoring the strength of Replicate's srRNA platform and its potential for oncology applications at the American Association for Cancer Research (AACR) Annual Meeting 2023....RBI-2000 encodes two distinct proteins on one RNA strand: one multimeric protein to promote generation of new immune cells, and another monomeric to prevent sterile inflammation, aberrant angiogenesis, and tumor invasiveness....Mice who had complete responses were rechallenged with tumor cells at 70 days post-treatment and successfully rejected the challenge, indicating robust immunological memory."

Preclinical • Oncology • Solid Tumor

Replicate Bioscience Shares New Preclinical srRNA Data at American Association for Cancer Research Annual Meeting 2023 (PRNewswire) - "Replicate Bioscience...announced two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in Orlando, Florida....'We look forward to sharing preclinical results with the AACR community demonstrating the potential of our srRNA technology platform and lead oncology program to substantially improve tumor control in estrogen receptor expressing breast cancers'."

Preclinical • Breast Cancer • Oncology • Solid Tumor